The kinetics of torque teno virus plasma DNA load shortly after engraftment predicts the risk of high-level CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients.
E AlbertCarlos SolanoE GiménezDaniele FocosiA PérezL MaceraJ L PiñanaJ C H BoludaF MaggiD NavarroPublished in: Bone marrow transplantation (2017)
Monitoring Torque teno virus (TTV) DNA load helps to estimate the risk of opportunistic infections in solid organ transplant recipients. We investigated whether the early kinetic pattern of plasma TTV DNA load after allogeneic hematopoietic stem cell transplantation (allo-HSCT) associates with subsequent CMV and EBV DNAemia. This study included 71 allo-HSCT patients. We found that the area under the curve (AUC) for log10 TTV DNA loads quantified by days 20 and 30 after transplantation (TTV DNA load AUC20-30), was significantly lower (P=0.036) in patients who subsequently developed CMV DNAemia requiring preemptive antiviral therapy (n=17) than in those who did not (n=8) or had no CMV DNAemia (n=19). Patients displaying TTV DNA load AUC20-30⩽2.8 copies × days × mL-1 were more likely to have high-level CMV DNAemia. A trend towards a direct correlation between TTV DNA AUC20-30 and CMV-specific interferon-γ CD8+ T-cell counts by day +30 was noted (P=0.095). However, this dynamic parameter was not useful for anticipating the occurrence of either CMV recurrences (n=12) or EBV DNAemia (n=34). In summary, it may be possible to identify a subset of allo-HSCT patients at a high risk of developing high-level CMV DNAemia by analyzing the kinetics of plasma TTV DNA load early after engraftment.
Keyphrases
- circulating tumor
- hematopoietic stem cell
- cell free
- single molecule
- end stage renal disease
- ejection fraction
- allogeneic hematopoietic stem cell transplantation
- nucleic acid
- stem cell transplantation
- peritoneal dialysis
- chronic kidney disease
- acute lymphoblastic leukemia
- epstein barr virus
- prognostic factors
- risk assessment
- stem cells
- immune response
- bone marrow
- high dose
- cell therapy
- patient reported outcomes